Mezagitamab  (Synonyms: TAK-079)

Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP)^[1][2][3].

Human IgG1 lambda1

Human IgG1 lambda1, Isotype Control

Humanized

Mezagitamab binds to CD38, allosterically inhibits the enzymatic activity of CD38, induces apoptosis by antibody-dependent cellular cytotoxicity (ADCC, activates immune cells such as NK cells) and complement-dependent cytotoxicity (CDC, activates the complement system)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Mezagitamab (0.03-100 mg/kg, iv, once or twice a week for 4-13 weeks) leads to the depletion of NK cells, B cells and T cells in cynomolgus monkey models^[4].
Mezagitamab (3 mg/kg, iv,once weekly for 8 weeks) prevents collagen-induced arthritis in cynomolgus monkey models^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2227490-52-8

Liquid

Colorless to light yellow

[Mezagitamab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 lambda

• 
  Immobilized CD38 Protein, Human can bind Mezagitamab. The EC₅₀ for this effect is 61.97 ng/mL.

• [1]. Abadier M, et al. Mezagitamab induces immunomodulatory effect in patients with relapsed/refractory multiple myeloma (RRMM)[J]. Blood, 2020, 136: 9.

  [2]. Jadoon Y, et al. Immunotherapy in multiple myeloma. Cancer Treat Res Commun. 2021;29:100468.  [Content Brief]

  [3]. Kuter DJ. Novel therapies for immune thrombocytopenia. Br J Haematol. 2022 Mar;196(6):1311-1328.  [Content Brief]

  [4]. Roepcke S, et al., Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial. Pharmacol Res Perspect. 2018 Jun;6(3):e00402.  [Content Brief]

  [5]. Korver W, et al., A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys. J Pharmacol Exp Ther. 2019 Aug;370(2):182-196.  [Content Brief]